THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, September 02, 2022
Recent advances include conditionally activated cytokines, inhibitors of key kinases, pathway-bridging bispecific antibodies, and endurant CAR T cells.
FREMONT, CA: Many researchers are concentrating on developing small-molecule inhibitors to recognise and target the important kinases that impair T-cell responses to tumour cells. Bispecific antibodies that can affect numerous complementary immune pathways and have a stronger therapeutic impact are being developed by some. Last but not least, some are developing chimeric antigen receptor (CAR) T-cell systems that combat solid tumours and get past the challenging obstacles of the tumour microenvironment (TME). The prodrug is an appealing cancer immunotherapy strategy. For instance, a prodrug given systemically might be inert until it reaches the TME, at which point it turns active and triggers a potent antitumor response. Although this strategy appears simple, bringing it into practice has been challenging. Tumour heterogeneity frequently causes prodrugs to be ineffectively activated.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Researchers deploy Predator, a protein engineering technology, to produce conditionally activated molecules called Indukines as a solution to this issue. Indukines, according to the manufacturer, can maximise tumour-specific death while decreasing unfavourable off-target consequences. The wild-type cytokine (for instance, IL-2 or IL-12), an inactivation domain to stop cytokine activity in the peripheral, a tumour-protease-sensitive linker that activates in the TME, and a half-life extension domain are the four modules that make up an indukine molecule. The WTX-124 prodrug, an IL-2 Indukine molecule produced by the business, has demonstrated promise in preclinical research. It offers a wider therapeutic window than recombinant human IL-2 and powerful anticancer efficacy by energising tumour-infiltrating CD8+ and CD4+ T cells.
Adults with renal cell carcinoma or melanoma are treated with aldesleukin, a synthetic version of IL-2. In fact, by boosting the activity and proliferation of T cells and B cells, systemic therapy with first-generation, high-dose aldesleukin can aid the immune system in killing cancer cells. But the medication has several drawbacks, including a low response rate (only 15 per cent), considerable toxicity (including capillary leak syndrome), a limited therapeutic index, a brief half-life, and a preference for regulatory T cell proliferation (Tregs). The Pharma Research and Early Development (pRED) team at Roche is working to overcome some of these restrictions. They fused a high-affinity anti-PD-1 antibody to a modified IL-2 version, for instance, to create a chimeric antibody-cytokine protein (IL-2v). IL-2Ra, also known as CD25, is not bound by IL-2v in the same way as it is by wild-type IL-2. As a result, CD25-mediated preferential targeting of Tregs and endothelial cells is eliminated.
The Pharma Research and Early Development (pRED) team is working to overcome some of these restrictions. They fused a high-affinity anti-PD-1 antibody to a modified IL-2 version, for instance, to create a chimeric antibody-cytokine protein (IL-2v). IL-2Ra, also known as CD25, is not bound by IL-2v in the same way as it is by wild-type IL-2. As a result, CD25-mediated preferential targeting of Tregs and endothelial cells is eliminated. Researchers are working on small-molecule HPK1 inhibitors.
More in News